FDA approves Perjeta for pre-operative breast cancer

The US Food and Drug Administration (FDA) has approved the targeted drug Perjeta (pertuzumab) for certain women with early stage breast cancer before surgery. The approval is specifically for women with HER2-positive, locally advanced, inflammatory or early stage breast cancer who are at high risk of having their breast cancer return or spread, or are at high risk of dying from the disease. The drug is meant to be used in combination with another targeted drug and with chemotherapy. Read more here.